Lupin Ltd — Investor Relations & Filings
Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Copy of Newspaper Publication | 2026-05-09 | English | |
| Analysts/Institutional Investor Meet/Con. Call Updates | 2026-05-08 | English | |
| Investor Presentation | 2026-05-07 | English | |
| Press Release | 2026-05-07 | English | |
| Change in Auditors | 2026-05-07 | English | |
| Dividend | 2026-05-07 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 44633064 | Copy of Newspaper Publication | 2026-05-09 | English | ||
| 44309389 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-05-08 | English | ||
| 43197610 | Investor Presentation | 2026-05-07 | English | ||
| 43197769 | Press Release | 2026-05-07 | English | ||
| 43161608 | Change in Auditors | 2026-05-07 | English | ||
| 43161822 | Dividend | 2026-05-07 | English | ||
| 43126919 | Outcome of Board Meeting | 2026-05-07 | English | ||
| 42186975 | Copy of Newspaper Publication | 2026-05-05 | English | ||
| 42195444 | Press Release | 2026-05-05 | English | ||
| 42205320 | ESOP/ESOS/ESPS | 2026-05-04 | English | ||
| 42196473 | Disclosure under SEBI Takeover Regulations | 2026-04-28 | English | ||
| 42164861 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-04-23 | English | ||
| 42272022 | Board Meeting — Board Meeting Intimation | 2026-04-22 | English | ||
| 42272037 | Board Meeting — Financial Results/Dividend/Other business matters | 2026-04-22 | English | ||
| 42183128 | Press Release | 2026-04-22 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ASTONEA LABS LIMITED
A CDMO specializing in pharmaceutical and cosmeceutical R&D…
|
544409 | IN | Manufacturing |
|
Astra Industrial Group
Diversified producer of pharmaceuticals, specialty chemical…
|
1212 | SA | Manufacturing |
|
AstraZeneca Pharma India Ltd.
Science-led biopharmaceutical organization focused on oncol…
|
ASTRAZEN | IN | Manufacturing |
|
AstraZeneca PLC
A global, science-led biopharmaceutical company developing …
|
AZN | GB | Manufacturing |
|
Astria Therapeutics, Inc.
Clinical-stage biopharma developing therapies for allergic …
|
ATXS | US | Manufacturing |
|
Asymchem Laboratories (Tianjin) Co., Ltd.
A leading CDMO providing comprehensive, integrated pharmace…
|
6821 | HK | Manufacturing |
|
Asymchem Laboratories (Tianjin) Co., Ltd.
Global CDMO providing integrated CMC services across the dr…
|
002821 | CN | Manufacturing |
|
ATAI Life Sciences N.V.
Develops psychedelic-inspired therapies for mental health d…
|
ATAI | NL | Manufacturing |
|
Atea Pharmaceuticals, Inc.
Clinical-stage biopharma developing oral antiviral therapie…
|
AVIR | US | Manufacturing |
|
Athira Pharma, Inc.
Biopharma firm developing small molecule therapeutics for n…
|
ATHA | US | Manufacturing |
Lupin Ltd via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61031/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61031 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61031 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61031 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61031}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Lupin Ltd (id: 61031)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.